Intended for HCPs, this resource outlines the key benefits REVOLADE can offer your ITP patients, including information on platelet response, dose adjustment, mechanism of action and safety profile as well as recommended treatment goals.
REVOLADE is indicated for the treatment of patients aged 1 year and above with primary ITP lasting 6 months or longer from diagnosis and who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).1
REVOLADE is indicated in adult patients with chronic HCV infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy.1
REVOLADE is indicated in adult patients with acquired SAA who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation.1
Abbreviations: HCP, healthcare professional; HCV, hepatitis C virus; ITP, immune thrombocytopenia; SAA, severe aplastic anaemia.
- REVOLADE Summary of Product Characteristics.